이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Mesenteric Vein Access for OPVT-Related Recurrent Variceal Bleeding: An Ambispective Cohort

2026년 6월 18일 업데이트: Tie Jun, Air Force Military Medical University, China

Percutaneous Mesenteric Vein Access for Interventional Management of Recurrent Variceal Bleeding in Occlusive Portal Vein Thrombosis: An Ambispective Cohort Study

Occlusive portal vein thrombosis (OPVT) is defined as complete thrombosis of the main portal vein trunk, resulting in total interruption of portal venous inflow and representing the most severe form of portal vein thrombosis. A small proportion of patients may remain asymptomatic for prolonged periods because of sufficient collateral compensation; however, most develop complications of portal hypertension when collateral flow is inadequate, including gastroesophageal variceal bleeding and ascites. Among these, gastroesophageal variceal bleeding is the most life-threatening, and its management is more challenging-with a higher risk of rebleeding-than in patients without portal vein thrombosis.

Occlusive portal vein thrombosis (OPVT) is defined as complete thrombosis of the main portal vein trunk, resulting in total interruption of portal venous inflow and representing the most severe form of portal vein thrombosis. A small proportion of patients may remain asymptomatic for prolonged periods because of sufficient collateral compensation; however, most develop complications of portal hypertension when collateral flow is inadequate, including gastroesophageal variceal bleeding and ascites. Among these, gastroesophageal variceal bleeding is the most life-threatening, and its management is more challenging-with a higher risk of rebleeding-than in patients without portal vein thrombosis.

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective minimally invasive therapy for portal hypertension-related complications; however, in OPVT, technical feasibility largely depends on successful portal vein recanalization. To improve TIPS success in OPVT, our group-together with domestic and international investigators-has explored several adjunctive access routes and technical modifications, including percutaneous transhepatic or transsplenic portal vein recanalization TIPS (PVR-TIPS); transjugular portal cavernous collateral-caval shunt (TCCS); transjugular mesenteric-caval shunt (TMCS); transjugular spleno-caval shunt (TSCS); and surgically assisted hybrid procedures. Although these strategies have improved technical success rates to some extent, their applicability remains limited. In patients with extensive thrombosis involving intrahepatic portal vein branches, in those without a feasible splenic venous puncture route, or in patients with prior splenectomy, percutaneous transhepatic and transsplenic approaches are often not possible. Moreover, in patients with poor hepatic reserve and/or ascites, laparotomy-assisted hybrid procedures substantially increase invasiveness and perioperative risk.

In this context, the present project aims to systematically investigate and evaluate ultrasound-guided percutaneous mesenteric vein (MV) puncture as an adjunctive access strategy for interventional treatment of OPVT. This technique uses ultrasound-guided percutaneous puncture of the MV to establish antegrade portal venous access, thereby facilitating subsequent portal vein recanalization and/or shunt creation.

연구 개요

상세 설명

Occlusive portal vein thrombosis (OPVT) is defined as complete thrombosis of the main portal vein trunk, resulting in interruption of portal venous inflow and representing a severe form of portal vein thrombosis. Although some patients may remain asymptomatic for prolonged periods because of collateral compensation, many develop clinically significant portal hypertension when collateral flow is inadequate-most notably gastroesophageal variceal bleeding and ascites. Gastroesophageal variceal bleeding is a major cause of morbidity and mortality and is often more difficult to control, with a higher risk of rebleeding, than variceal bleeding in patients without portal vein thrombosis.

Transjugular intrahepatic portosystemic shunt (TIPS) is an established minimally invasive therapy for complications of portal hypertension. In OPVT, however, technical feasibility often hinges on successful portal vein recanalization. Multiple adjunctive techniques have been developed to improve feasibility in selected patients, including percutaneous transhepatic or transsplenic portal vein recanalization TIPS (PVR-TIPS), portal cavernous collateral-caval shunt procedures, mesenteric-caval or spleno-caval shunts, and surgically assisted hybrid approaches. Despite these advances, a meaningful subset of patients remain poor candidates because of extensive intrahepatic portal branch thrombosis, absence of a feasible splenic puncture route, prior splenectomy, or prohibitive risk for laparotomy-assisted hybrid procedures (e.g., in patients with limited hepatic reserve and/or ascites).

This study will evaluate ultrasound-guided percutaneous mesenteric vein (MV) puncture as an adjunctive access strategy to enable interventional decompression of the portal venous system in OPVT. Using real-time ultrasound, percutaneous MV access is obtained to establish an antegrade working channel. This channel is then used to facilitate portal vein recanalization and/or shunt creation when standard access routes are not feasible or have failed.

Study design and setting: Ambispective, exploratory, single-center clinical study.

Population: Patients with imaging-confirmed OPVT and recurrent gastroesophageal variceal bleeding, particularly those in whom conventional interventional access routes (e.g., transjugular-only approaches, percutaneous transhepatic access, or transsplenic access) are limited, infeasible, or have been unsuccessful.

Intervention (Stepwise Intra-procedural Strategy)

After establishing MV access under ultrasound guidance, operators will follow a predefined escalation algorithm based on intra-procedural anatomy and technical feasibility:

MV-assisted PVR-TIPS (preferred): Antegrade catheter/guidewire manipulation via MV access to attempt recanalization of the occluded main portal vein trunk. A catheter or balloon may be positioned as a target to facilitate completion of a standard TIPS via the transjugular route.

MV-assisted collateral-to-caval shunt (secondary): If main portal vein recanalization is not achievable, selective catheterization of an eligible collateral (e.g., diameter ≥6 mm) may be performed, with target-marker assistance to create a collateral-to-inferior vena cava shunt via the transjugular route.

Extrahepatic MV-to-caval shunt (backup): If neither main portal vein recanalization nor a suitable collateral is available, an extrahepatic MV-to-inferior vena cava shunt tract may be created through the established MV access as an alternative portal decompression strategy.

Outcomes (Overview) The study will assess: (1) technical feasibility (e.g., successful MV access; successful creation of a functioning shunt via any pathway), (2) procedural safety (peri-procedural and follow-up complications), and (3) clinical effectiveness, including control of portal hypertension-related bleeding (e.g., rebleeding during follow-up) and other manifestations of portal hypertension, as applicable.

연구 유형

중재적

등록 (추정된)

15

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Shaanxi
      • Xi'an, Shaanxi, 중국, 710032
        • Air Force Medical University
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria

  1. Confirmed OPVT, as demonstrated by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
  2. History of at least two episodes of esophagogastric variceal bleeding.
  3. Ineligible for, or have previously failed, conventional transjugular intrahepatic portosystemic shunt (TIPS) or percutaneous transhepatic/transsplenic access approaches, including but not limited to extensive thrombosis of intrahepatic portal vein branches, prior splenectomy, or previous unsuccessful attempts.
  4. Child-Pugh score ≤12, with anticipated tolerance of the interventional procedure.

Exclusion Criteria

  1. Thrombosis or severe stenosis of the superior mesenteric vein (SMV), precluding its use as a percutaneous access route.
  2. Severe cardiac, pulmonary, or renal insufficiency that precludes tolerance of the procedure.
  3. Uncorrectable coagulopathy.
  4. Life expectancy <3 months, or inability to comply with scheduled follow-up visits.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Percutaneous mesenteric vein-assisted interventional treatment
Eligible patients include those with imaging-confirmed OPVT and recurrent gastroesophageal variceal bleeding, particularly when conventional interventional access routes (e.g., transjugular-only approaches, percutaneous transhepatic access, or transsplenic access) are limited, infeasible, or have failed. Under real-time ultrasound guidance, percutaneous mesenteric vein (MV) access is obtained to establish an antegrade working channel, which is then used to facilitate portal vein recanalization and/or shunt creation.

Intervention (stepwise intra-procedural strategy). After MV access is established under ultrasound guidance, operators will follow a predefined escalation algorithm based on anatomy and feasibility:

MV-assisted PVR-TIPS (preferred): Using antegrade catheter/guidewire manipulation via MV access, attempt recanalization of the occluded main portal vein trunk. A catheter or balloon may be positioned as a target to complete standard TIPS via the transjugular route.

MV-assisted collateral-to-caval shunt (secondary): If main portal vein recanalization is not achievable, catheterize an eligible collateral (e.g., ≥6 mm) and, with target-marker assistance, create a collateral-to-inferior vena cava shunt via the transjugular route.

Extrahepatic MV-to-caval shunt (backup): If neither main portal vein recanalization nor a suitable collateral is available, create an extrahepatic MV-to-inferior vena cava shunt tract through MV access as an alternative portal decompression strategy.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Technical success of the index procedure (overall)
기간: During the procedure (index hospitalization)
Successful creation of a functioning portosystemic shunt using the study strategy (MV-assisted PVR-TIPS, MV-assisted collateral-to-caval shunt, or extrahepatic MV-to-caval shunt), confirmed by completion angiography demonstrating shunt patency/flow and effective portal decompression as assessed intra-procedurally per operator judgment and standard imaging criteria.
During the procedure (index hospitalization)
Safety-major procedure-related adverse events
기간: From procedure through 30 days post-procedure.
Incidence of major adverse events related to MV puncture and/or shunt creation (e.g., clinically significant intraperitoneal hemorrhage, bowel/mesenteric injury, sepsis, procedure-related death, or other events meeting predefined serious adverse event criteria).
From procedure through 30 days post-procedure.

2차 결과 측정

결과 측정
측정값 설명
기간
Variceal rebleeding
기간: 6 months post-procedure.
Incidence of recurrent gastroesophageal variceal bleeding after the index procedure, defined clinically (e.g., hematemesis/melena with endoscopic and/or imaging confirmation when available) and requiring hospital presentation, transfusion, endoscopic therapy, radiologic intervention, or resulting in death.
6 months post-procedure.
Shunt patency (primary patency)
기간: 6 months post-procedure.
Proportion of patients with a patent shunt without need for re-intervention, assessed by Doppler ultrasound and/or contrast-enhanced CT/MR venography per the follow-up schedule.
6 months post-procedure.
Hepatic encephalopathy (new onset or worsening)
기간: From procedure through 6 months post-procedure.
Incidence and severity of hepatic encephalopathy after the procedure, graded using a standardized clinical scale per institutional practice (e.g., West Haven criteria) and requiring initiation/escalation of therapy and/or hospitalization.
From procedure through 6 months post-procedure.
Overall survival
기간: 6 months post-procedure
All-cause mortality following the index procedure.
6 months post-procedure

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 1일

기본 완료 (추정된)

2028년 6월 30일

연구 완료 (추정된)

2028년 6월 30일

연구 등록 날짜

최초 제출

2026년 6월 18일

QC 기준을 충족하는 최초 제출

2026년 6월 18일

처음 게시됨 (실제)

2026년 6월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 18일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다